You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of NET-Selective Piperidine-Based PET Ligand

    SBC: Acenta Discovery, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): World-wide public health surveys point to an increasing global health burden resulting from serious brain disorders, particularly mood-related disorders such as depression. The economic burden of depression alone is immense. Of the $83.1 billion spent in 2000 on the treatment of depression and related expenses, $26.1 billion (31 percent) were direct medical cos ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  2. Bacterial vector vaccine: Her-2/neu expressing tumors

    SBC: ADVAXIS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Advaxis will develop a novel Listeria monocytogenes based vaccine against the human HER-2/neu protein that will be a safe and effective therapeutic vaccine for the treatment of HER-2/neu overexpressing breast carcinomas. Breast cancer, the most common type of cancer in women, is a complex disease with no single causative agent or event. There are several tumor- ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Neuromorphic Control System for Powered Limb Splints

    SBC: Advensys, LLC            Topic: A04T009

    AdveNSys will develop a suite of products to provide new orthotic and prosthetic options for people with lower limb dysfunction or lower limb amputation. We will enhance our biologically-inspired adaptive neuromorphic control systems technology and integrate it with biomorphic compliant actuators, advanced sensor systems, and lightweight orthotic/prosthetic components to produce a suite of produc ...

    STTR Phase II 2005 Department of DefenseArmy
  4. Fabrication of 3D Photonic Crystals in the RF Range for Man-Portable Antenna Applications

    SBC: Antennovation            Topic: A05T017

    Antennovation and the Pennsylvania State University propose to develop novel new electromagnetic bandgap (EBG) materials in conjunction with miniaturized broadband antennas for use in man-portable antenna applications. The proposed antenna/EBG system will be designed to be low-profile, compact, and light-weight for helmet-mounted antennas and/or other body-worn applications. The frequency range o ...

    STTR Phase I 2005 Department of DefenseArmy
  5. Automated Test of Word Recognition- Phase II

    SBC: AUDIOLOGY, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Over 5 million word recognition tests are administered annually by audiologists in the United States with an associated cost of more than $100 million. These tests are currently performed manually by highly trained audiologists. This application describes the Phase II development of automated clinical speech recognition tests using clinical test recordings and ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Audiometric Earphone- Phase 1

    SBC: AUDIOLOGY, INC            Topic: N/A

    DESCRIPTION (provided by applicant): This project seeks to develop an earphone for diagnostic audiometry with features that will significantly increase the efficiency and decrease the cost of routine hearing testing. The most-often used earphones emply a supra-aural design that has several undesirable characteristics, including 1) an "occlusion effect", an artificial increase in sensitivity to bon ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Vasoactive Therapeutic

    SBC: Azerx, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Approximately 30,000 patients per year in the US suffer from subarachnoid hemorrhage (SAH). Although SAH represents only 5-10% of strokes, its impact is proportionally much higher because SAH patients are typically younger (mean age is 50 years) than other stroke patients. Nearly half of SAH patients die from either the initial hemorrhage or secondary compli ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Terrain Analysis for Human-Robot Interaction (TAH-RI)

    SBC: CHI SYSTEMS INC            Topic: A04T001

    Understanding the right thing to do in the battlespace is contingent on knowledge of the terrain and its tactical importance for military operations (e.g., terrain restricts or enhances abilities to observe, move, and shoot). The product of this Phase II effort will be TAH-RI, a COTS software component for systems developers, enabling them to easily make systems capable of identifying terrain fea ...

    STTR Phase II 2005 Department of DefenseArmy
  9. Modified Tetracycline Effect on Sepsis-Induced Mortality

    SBC: Collagenex Pharmaceuticals, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): It was our Specific Aim in Phase I to: 1) develop a clinically relevant indirect sepsis-induced acute respiratory distress syndrome (ARDS) model and 2) utilize this model to determine the efficacy of prophylactic COL-3 in preventing the onset of ARDS. Both goals of our Phase I study were achieved and the results are as follows: 1) we successfully developed an ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  10. New anti-complement therapy to reduce reperfusion injury

    SBC: ENDOPROTECH, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of this proposal is to provide proof-of-concept that a novel therapy that prevents complement activation could be effective in reducing ischemia reperfusion injury (IRI) in transplanted organs. Complement activation after IRI in transplanted organs is a well-known phenomenon that may be responsible for delayed graft function and the hastening of ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government